Glioblastoma multiforme
| Glioblastoma | |
|---|---|
| Synonyms | glioblastoma multiforme, grade IV astrocytoma |
 |
|
| Coronal MRI with contrast of a glioblastoma WHO grade IV in a 15-year-old male | |
| Classification and external resources | |
| Specialty | Oncology, neurosurgery |
| ICD-10 | C71 |
| ICD-9-CM | 191 |
| ICD-O | M9440/3 |
| OMIM | 137800 |
| DiseasesDB | 29448 |
| eMedicine | neuro/147 med/2692 |
| MeSH | D005909 |
Glioblastoma, also known as glioblastoma multiforme (GBM), is the most aggressive cancer that begins within the brain. Signs and symptoms of glioblastoma are initially non-specific. They may include headaches, personality changes, nausea, and symptoms similar to those of a stroke. Worsening of symptoms is often rapid. This can progress to unconsciousness.
The cause of most cases is unclear. Uncommon risk factors include genetic disorders such as neurofibromatosis and Li Fraumeni syndrome and previous radiation therapy. Glioblastomas represent 15% of brain tumors. They can either start from normal brain cells or develop from an already existing low-grade astrocytoma. The diagnosis is typically made by a combination of CT scan, MRI scan, and tissue biopsy.
There is no clear way to prevent the disease. Typically treatment involves surgery after which chemotherapy and radiation therapy are used. The medication temozolomide is frequently used as part of chemotherapy. High dose steroids may be used to help reduce swelling and decrease symptoms. It is unclear whether trying to remove all or simply most of the cancer is better.
Despite maximum treatment, the cancer usually recurs. The most common length of survival following diagnosis is 12 to 15 months with less than 3% to 5% of people surviving longer than five years. Without treatment survival is typically 3 months. It is the most common cancer that begins within the brain and the second most common brain tumor after meningioma. About 3 per 100,000 people develop the disease a year. It most often begins around 64 years of age and occurs more commonly in males than females.Immunotherapy is being studied in glioblastoma with promising results.
...
Wikipedia